FATE THERAPEUTICS INC Restricted Cash and Cash Equivalents, Noncurrent
FATE THERAPEUTICS INC (FATE) had Restricted Cash and Cash Equivalents, Noncurrent of $10.05 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Restricted Cash and Cash Equivalent, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2026-08-13
- 2026-06-30: Restricted Cash and Cash Equivalents, Noncurrent $10.05M.
- 2026-03-31: Restricted Cash and Cash Equivalents, Noncurrent $10.05M.
- 2025-12-31: Restricted Cash and Cash Equivalents, Noncurrent $10.23M.
- 2025-09-30: Restricted Cash and Cash Equivalents, Noncurrent $10.23M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2026-06-30 | $10.05M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $10.05M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $10.23M 10-K · filed 2026-02-26 |
| 2025-09-30 | $10.23M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $10.23M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $10.23M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $10.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.23M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $15.18M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $15.18M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $15.18M 10-K · filed 2025-03-05 |
| 2023-09-30 | $15.18M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $15.18M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $15.23M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $15.23M 10-K · filed 2024-02-26 |
| 2022-09-30 | $15.23M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $15.23M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $15.23M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $15.23M 10-K · filed 2023-02-28 |
| 2021-09-30 | $15.23M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $15.23M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $15.23M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $15.23M 10-K · filed 2023-02-28 |
| 2020-09-30 | $15.23M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $15.23M 10-Q · filed 2021-08-04 |
| 2020-03-31 | $15.23M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $227.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $227.00K 10-Q · filed 2020-11-05 |
| 2019-06-30 | $227.00K 10-Q · filed 2020-08-05 |
| 2019-03-31 | $227.00K 10-Q · filed 2020-05-11 |
| 2018-12-31 | $227.00K 10-K · filed 2021-02-24 |
| 2018-09-30 | $227.00K 10-Q · filed 2019-11-05 |
| 2018-06-30 | $227.00K 10-Q · filed 2018-08-06 |
| 2018-03-31 | $122.00K 10-Q · filed 2018-05-10 |
| 2017-12-31 | $122.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $122.00K 10-Q · filed 2017-11-01 |
| 2017-06-30 | $122.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | $122.00K 10-Q · filed 2017-05-15 |
| 2016-12-31 | $122.00K 10-K · filed 2019-03-05 |
| 2016-09-30 | $122.00K 10-Q · filed 2016-11-07 |
| 2016-06-30 | $122.00K 10-Q · filed 2016-08-08 |
| 2016-03-31 | $122.00K 10-Q · filed 2016-05-09 |
| 2015-12-31 | $122.00K 10-K · filed 2018-03-05 |
| 2015-09-30 | $122.00K 10-Q · filed 2015-11-03 |
| 2015-06-30 | $122.00K 10-Q · filed 2015-08-05 |
| 2015-03-31 | $122.00K 10-Q · filed 2015-05-07 |
| 2014-12-31 | $122.00K 10-K · filed 2016-03-03 |
| 2014-09-30 | $122.00K 10-Q · filed 2014-11-12 |
| 2014-06-30 | $122.00K 10-Q · filed 2014-08-12 |
| 2014-03-31 | $122.00K 10-Q · filed 2014-05-13 |
| 2013-12-31 | $122.00K 10-K · filed 2015-03-12 |
| 2013-09-30 | $122.00K 10-Q · filed 2013-11-13 |
| 2012-12-31 | $122.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |